{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:25:13Z","timestamp":1793823913703,"version":"4.6.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The outlook for individuals dealing with metastatic or recurrent cervical cancer is still unfavorable, and existing biomarkers that assess the effectiveness of immune checkpoint inhibitors (ICIs) have certain drawbacks. Our objective was to assess the predictive importance of the combined neutrophil-to-lymphocyte ratio (Combined.NLR), incorporating both pre-treatment and post-treatment measurements in this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort analysis, performed at one center, encompassed 148 individuals diagnosed with metastatic or recurrent cervical cancer who underwent treatment with ICIs. Patients were categorized into the Combined.NLR groups according to the median neutrophil-to-lymphocyte ratio (NLR) values obtained before and after treatment. The relationship between the Combined.NLR and progression-free survival (PFS) was examined through Cox regression analysis. A prognostic nomogram that includes various factors was created.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Combined.NLR was identified as an independent prognostic factor for PFS. Individuals classified in the poor group exhibited a notably increased risk of disease progression in comparison to those in the good group [hazard ratio (HR) = 1.355, 95% confidence interval (CI): 1.006\u20131.824, p = 0.046]. The nomogram, which integrated the Combined.NLR, histological type, PD-L1 expression, the count of previous treatment lines, and the presence of multi-organ metastasis demonstrated a concordance index of 0.70. Calibration curves showed a strong correlation between the predicted results and the actual outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The Combined.NLR is a dynamic and readily accessible prognostic marker. The developed nomogram provides individualized risk prediction for individuals with metastatic or recurrent cervical cancer, potentially aiding clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1811428","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:36:04Z","timestamp":1776144964000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Combined neutrophil-to-lymphocyte ratio and nomogram for predicting progression-free survival in recurrent\/metastatic cervical cancer treated with immune checkpoint inhibitors"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhen","family":"Xu","sequence":"first","affiliation":[{"name":"Gene Joint Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyue","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqin","family":"Bai","sequence":"additional","affiliation":[{"name":"Gene Joint Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32470-x","article-title":"Cervical cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35369","article-title":"Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: The urgent need to address inequalities in cervical cancer","volume":"157","author":"Li","year":"2025","journal-title":"Int J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-023-03552-3","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with cervical cancer - Update 2023","volume":"482","author":"Cibula","year":"2023","journal-title":"Virchows Archiv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02769","article-title":"Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix","volume":"41","author":"Peters","year":"2023","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01249-z","article-title":"Novel therapeutics for recurrent cervical cancer: Moving towards personalized therapy","volume":"80","author":"Cohen","year":"2020","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103308","article-title":"A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer","volume":"85","author":"Wen","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2008.05.006","article-title":"Chemotherapy for recurrent cervical cancer","volume":"34","author":"Pectasides","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2023.34.e60","article-title":"Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer","volume":"34","author":"Kotaka","year":"2023","journal-title":"J Gynecologic Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01206-x","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(19)30043-8","article-title":"Immune checkpoint inhibitors in non-small-cell lung cancer: Key to long-term survival","volume":"7","author":"Dingemans","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00914","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: Final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.006","article-title":"Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy","volume":"43","author":"Wang","year":"2025","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10555-025-10260-8","article-title":"Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly","volume":"44","author":"Adashek","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010311","article-title":"Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types","volume":"13","author":"Gandara","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1679365","article-title":"Advancing immunotherapy for esophageal cancer: Decoding the roles of PD-L1, TME, and tumor-intrinsic biomarkers","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1235158","article-title":"The combination of baseline neutrophil to lymphocyte ratio and dynamic changes during treatment can better predict the survival of osteosarcoma patients","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879560","article-title":"Hematological prognostic scoring system can predict overall survival and can indicate response to immunotherapy in patients with osteosarcoma","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00030","article-title":"Meta-analysis of hematological biomarkers as reliable indicators of soft tissue sarcoma prognosis","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03000-8","article-title":"Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR","volume":"71","author":"Kobayashi","year":"2022","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0222-4","article-title":"Tumour-associated neutrophils in patients with cancer","volume":"16","author":"Shaul","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09278-3","article-title":"Neutrophils drive vascular occlusion, tumour necrosis and metastasis","volume":"645","author":"Adrover","year":"2025","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.06.015","article-title":"Tumor-infiltrating lymphocytes: A new hope","volume":"42","author":"Sarnaik","year":"2024","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1482746","article-title":"Prognostic value of inflammatory markers NLR, PLR, LMR, dNLR, ANC in melanoma patients treated with immune checkpoint inhibitors: A meta-analysis and systematic review","volume":"15","author":"Ou","year":"2024","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"31528","DOI":"10.1038\/s41598-024-82976-6","article-title":"Systemic immune-inflammatory index predict short-term outcome in recurrent\/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2022.101040","article-title":"High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent\/metastatic cervical cancer treated with immune checkpoint inhibitors","volume":"42","author":"Calo","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1139809","article-title":"Effects of peripheral blood neutrophil\/lymphocyte ratio levels and their changes on the prognosis of patients with early cervical cancer","volume":"13","author":"Du","year":"2023","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1506355","article-title":"Prognostic significance of combined PD-L1 expression in Malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab","volume":"15","author":"Lee","year":"2024","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5410","article-title":"Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses from the KEYNOTE-826 randomized clinical trial","volume":"10","author":"Tewari","year":"2024","journal-title":"JAMA Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2025.200323","article-title":"The immunological heterogeneity of squamous cell carcinoma and adenocarcinoma of the uterine cervix: A systematic review","volume":"20","author":"Strikwerda","year":"2025","journal-title":"Tumour Virus Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.S358302","article-title":"Efficacy and prognostic factors for response to PD-1 inhibitors in advanced cervical carcinoma: A retrospective study","volume":"16","author":"Cheng","year":"2022","journal-title":"Drug Des Dev Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1701319","article-title":"Cadonilimab rechallenge in patients with recurrent or metastatic cervical cancer following prior PD-1\/PD-L1 inhibitor failure: A retrospective multicenter study","volume":"16","author":"Yu","year":"2025","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1662605","article-title":"Development and validation of immunotherapy nomogram for predicting the efficacy and prognosis of recurrent and metastatic cervical cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02951-7","article-title":"Real-world safety and efficacy of immune checkpoint inhibitors in Japanese patients with persistent, recurrent, or metastatic cervical cancer: A multicenter prospective and retrospective study","volume":"31","author":"Kitami","year":"2026","journal-title":"Int J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i41.11877","article-title":"Nomograms for colorectal cancer: A systematic review","volume":"21","author":"Kawai","year":"2015","journal-title":"World J Gastroenterol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1811428\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:36:04Z","timestamp":1776144964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1811428\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1811428"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1811428","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1811428"}}